At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 281 enrolled
Drug / intervention
FTY720 +1 moredrug
Likely dose
Placebo 1.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase
In Brief
A Phase 2 clinical trial evaluating FTY720 and Placebo for Multiple Sclerosis. Completed, enrolled 281 participants across 26 sites in 11 countries.
Detailed Summary
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada, Denmark, Finland, France, Germany, Italy, Poland, Portugal, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2003
First PostedJun 2006
Primary CompletionApr 2011
TodayJul 2026
First PostedJun 2, 2006
Enrollment StartMay 1, 2003
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 20.1 years ago
Interventions
FTY720drug
FTY720 capsule was taken orally once a day
Placebodrug
Placebo 1.25 mg capsule was given once daily